Trial Profile
MAintain the Efficacy and Safety in Treatment of Schizophrenia After Switching to Long-acTing Injectable aRipiprazole From Oral Atypical Antipsychotics
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Dec 2021
Price :
$35
*
At a glance
- Drugs Aripiprazole (Primary) ; Aripiprazole (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Acronyms MAESTRO
- Sponsors Korea Otsuka Pharmaceutical
- 16 Dec 2021 Status changed from active, no longer recruiting to completed.
- 15 Jul 2021 Planned End Date changed from 30 Sep 2021 to 3 Dec 2021.
- 15 Jul 2021 Planned primary completion date changed from 31 Aug 2021 to 3 Dec 2021.